Lumiracoxib inhibits cyclo-oxygenase 2 completely at the 50 mg dose: is liver toxicity avoidable by adequate dosing?
作者： B Hinz , B Renner , O Cheremina , D Besz , O Zolk
关键词: Cyclo oxygenase 2 、 Osteoarthritis 、 Medicine 、 Dosing 、 Clinical trial 、 Lumiracoxib 、 Pharmacology 、 Liver toxicity 、 Therapeutic effect 、 Anesthesia 、 Symptomatic treatment
摘要: Lumiracoxib is a selective cyclo-oxygenase 2 (COX-2) inhibitor used for symptomatic treatment of osteoarthritis and acute pain. Among the available COX-2 inhibitors, lumiracoxib only compound with gastrointestinal benefit in patients that has been demonstrated large outcome study.1 Several countries have approved at doses 200 mg (for osteoarthritis) 400 pain), both them exceeding dose necessary to inhibit time maximal plasma concentration.2 In line this notion, one clinical trial reported knee or hip randomised receive 50, 100 twice daily once experienced comparable pain relief.3 Regrettably, systematical analysis dose-dependent therapeutic effects lacking. The interest …
uni-konstanz.de
sci-hub.se 参考文章(7)
Thomas J. Schnitzer, Jannie Beier, Piet Geusens, Paul Hasler, Sanjay K. Patel, Ingo Senftleber, Xavier Gitton, Alan Moore, Victor S. Sloan, Gyula Poór, Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial Arthritis Care and Research. ,vol. 51, pp. 549- 557 ,(2004) , 10.1002/ART.20525
Ronald Esser, Carol Berry, Zhengming Du, Janet Dawson, Alyson Fox, Roger A Fujimoto, William Haston, Earl F Kimble, Julie Koehler, Jane Peppard, Elizabeth Quadros, Joseph Quintavalla, Karen Toscano, Laszlo Urban, John van Duzer, Xiaoli Zhang, Siyuan Zhou, Paul J Marshall, Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase‐2 British Journal of Pharmacology. ,vol. 144, pp. 538- 550 ,(2005) , 10.1038/SJ.BJP.0706078
J. H. Rubenstein, L. Laine, Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Alimentary Pharmacology & Therapeutics. ,vol. 20, pp. 373- 380 ,(2004) , 10.1111/J.1365-2036.2004.02092.X
Olga Cheremina, Kay Brune, Burkhard Hinz, A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma. Biomedical Chromatography. ,vol. 20, pp. 1033- 1037 ,(2006) , 10.1002/BMC.633
Thomas J Schnitzer, Gerd R Burmester, Eduardo Mysler, Marc C Hochberg, Michael Doherty, Elena Ehrsam, Xavier Gitton, Gerhard Krammer, Bernhard Mellein, Patrice Matchaba, Alberto Gimona, Christopher J Hawkey, None, Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. The Lancet. ,vol. 364, pp. 665- 674 ,(2004) , 10.1016/S0140-6736(04)16893-1
Ying Li, J. Greg Slatter, Zhoupeng Zhang, Yan Li, George A. Doss, Matthew P. Braun, Ralph A. Stearns, Dennis C. Dean, Thomas A. Baillie, Wei Tang, In vitro metabolic activation of lumiracoxib in rat and human liver preparations Drug Metabolism and Disposition. ,vol. 36, pp. 469- 473 ,(2008) , 10.1124/DMD.107.019018
P Patrignani, Maria R Panara, A Greco, O Fusco, C Natoli, Stefano Iacobelli, F Cipollone, Antonina Ganci, Christophe Creminon, J Maclouf, None, Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. Journal of Pharmacology and Experimental Therapeutics. ,vol. 271, pp. 1705- 1712 ,(1994)